In Reply: Response to Marioni

Abstract

We are grateful for the insightful comments made by Dr Marioni regarding the evidence for survivin as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC) [1], omitted from our review for reasons of space. We agree that targeting survivin in HNSCC is a strategy worthy of exploration, though, at present, limited numbers of patients treated in clinical trials [2,3]